Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis

Abdoellakhan, R. A., Miah, I. P., Khorsand, N., Meijer, K. & Jellema, K., Feb-2017, In : Neurocritical care. 26, 1, p. 64-69 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

Millions of patients receive vitamin K antagonist (VKA) therapy worldwide. Annually 0.2-1 % of all VKA users develops an intracranial hemorrhage (ICH). Prothrombin complex concentrate (PCC) is administered to restore the INR

In a before and after design, we compared successful achievement of an INR

A median dosage of 1750 IU was given per patient in the variable dose group (n = 25) versus 1000 IU in the fixed dose group (n = 28). In the intention-to-treat analysis, 96 % achieved an INR

The fixed dose protocol necessitates additional PCC infusions more frequently to achieve a target INR

Original languageEnglish
Pages (from-to)64-69
Number of pages6
JournalNeurocritical care
Issue number1
Publication statusPublished - Feb-2017


  • Intracranial hemorrhage, Hemostasis, International normalized ratio, Prothrombin complex concentrate, Vitamin K antagonist, SPONTANEOUS INTRACEREBRAL HEMORRHAGE, ANTICOAGULATION, REVERSAL, GUIDELINES, MANAGEMENT, MORTALITY, FRENCH

Download statistics

No data available

ID: 43997465